Search hospitals > Ohio > Dayton
Dayton Children's Hospital
Claim this profileDayton, Ohio 45404
Global Leader in Cancer
Global Leader in Adult T-Cell Leukemia/Lymphoma
Conducts research for Brain Tumor
Conducts research for Lymphoma
Conducts research for Acute Lymphoblastic Leukemia
257 reported clinical trials
5 medical researchers
Summary
Dayton Children's Hospital is a medical facility located in Dayton, Ohio. This center is recognized for care of Cancer, Adult T-Cell Leukemia/Lymphoma, Brain Tumor, Lymphoma, Acute Lymphoblastic Leukemia and other specialties. Dayton Children's Hospital is involved with conducting 257 clinical trials across 422 conditions. There are 5 research doctors associated with this hospital, such as Mukund G. Dole, Alvin C Jones, MD, Shobhan Vachhrajani, MD, PhD, and Jeffrey Pence, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage I
Stage II
2Adult T-Cell Leukemia/Lymphoma
Global LeaderNTRK1 positive
NTRK positive
Stage II
Top PIs
Mukund G. DoleDayton Children's Hospital8 years of reported clinical research
Expert in Cancer
Expert in Brain Tumor
53 reported clinical trials
105 drugs studied
Alvin C Jones, MDDayton Children's Hospital5 years of reported clinical research
Studies Scoliosis
Studies Adolescent Idiopathic Scoliosis
1 reported clinical trial
1 drug studied
Shobhan Vachhrajani, MD, PhDDayton Children's Hospital6 years of reported clinical research
Studies Traumatic Brain Injury
Studies Traumatic Brain Hemorrhage
1 reported clinical trial
1 drug studied
Jeffrey Pence, MDDayton Children's Hospital6 years of reported clinical research
Studies Traumatic Brain Injury
Studies Traumatic Brain Hemorrhage
1 reported clinical trial
1 drug studied
Clinical Trials running at Dayton Children's Hospital
Acute Lymphoblastic Leukemia
Wilms Tumor
Testicular cancer
Cancer
Adult T-Cell Leukemia/Lymphoma
Testicular Carcinoma
Lymphoma
Brain Tumor
Germ Cell Tumors
Ovarian Carcinoma
Levocarnitine
for Chemotherapy-Related Liver Protection in Leukemia and Lymphoma
This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care chemotherapy for the treatment of acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), and mixed phenotype acute leukemia (MPAL). However, in adolescent and young adults (AYA) ages 15-39 years, liver toxicity from asparaginase is common and often prevents delivery of planned chemotherapy, thereby potentially compromising outcomes. Some groups of people may also be at higher risk for liver damage due to the presence of fat in the liver even before starting chemotherapy. Patients who are of Japanese descent, Native Hawaiian, Hispanic or Latinx may be at greater risk for liver damage from chemotherapy for this reason. Carnitine is a naturally occurring nutrient that is part of a typical diet and is also made by the body. Carnitine is necessary for metabolism and its deficiency or absence is associated with liver and other organ damage. Levocarnitine is a drug used to provide extra carnitine. Laboratory and real-world usage of the dietary supplement levocarnitine suggests its potential to prevent or reduce liver toxicity from asparaginase. The overall goal of this study is to determine whether adding levocarnitine to standard of care chemotherapy will reduce the chance of developing severe liver damage from asparaginase chemotherapy in ALL, LL and/or MPAL patients.
Recruiting2 awards Phase 3
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3
Inotuzumab Ozogamicin
for Leukemia and Lymphoma
This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back (relapsed) or does not respond to treatment (refractory). Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called ozogamicin. Inotuzumab attaches to CD22 positive cancer cells in a targeted way and delivers ozogamicin to kill them.
Recruiting1 award Phase 210 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Dayton Children's Hospital?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.